secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2026-04-13T23:59:59+00:00
Accession:  0001104659-26-042141
Event type: regulatory
Sentiment:  negative
Materiality: 0.95
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA issues second CRL for Replimune's RP1 BLA; company plans layoffs and manufacturing scale-back
--------------------------------------------------------------------------------

- FDA second Complete Response Letter for BLA of RP1 plus nivolumab for advanced melanoma; Replimune disagrees with decision.
- Without timely accelerated approval, further development of RP1 not viable; company eliminating jobs and scaling back U.S. manufacturing.
- IGNYTE trial: 34% response rate, median duration 24.8 months for RP1 plus nivolumab in patients progressing on anti-PD-1.
- Company cites inconsistent FDA process: new review team, contradictions from September 2025 Type A meeting, and lack of communication.
- Approximately 8,500 advanced melanoma deaths annually in U.S.; CEO says regulatory failure denies patients needed treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465926042141/0001104659-26-042141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465926042141/tm2611633d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-042141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer